Six people with treatment-resistant immune thrombocytopenia (ITP) and underlying systemic lupus erythematosus (SLE) all achieved clinical responses to CAR…
Articles by Steve Bryson PhD
A man’s severe case of treatment-resistant immune thrombotic thrombocytopenic purpura (iTTP) — which resulted in severe anemia despite more…
A new case study describes a family with platelet-type von Willebrand disease (PT-VWD), a rare bleeding condition often mistaken for…
A lack or delayed response to Cablivi (caplacizumab-yhdp), when used alongside standard therapy to treat acute episodes of immune-mediated…
U.S. researchers have created a prediction tool — one that uses laboratory tests collected at the time of diagnosis —…
Researchers are developing a potential treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) that promotes immune tolerance rather than immunosuppression,…
A real-world study has found that during hospitalizations among people with von Willebrand disease (VWD), VWF replacement therapy with…
Treatment with Cablivi (caplacizumab-yhdp) as an add-on to standard therapy significantly reduced the number of daily plasma exchange (PEX) treatments…
Scientists have developed a gene-editing therapy to selectively disable the genetic mutations responsible for Von Willebrand disease (VWD) type…
Adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are in remission experience worse health-related quality of life (HRQoL), anxiety,…